1. Home
  2. BRID vs ANVS Comparison

BRID vs ANVS Comparison

Compare BRID & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgford Foods Corporation

BRID

Bridgford Foods Corporation

HOLD

Current Price

$7.58

Market Cap

72.0M

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.78

Market Cap

46.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRID
ANVS
Founded
1932
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.0M
46.5M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
BRID
ANVS
Price
$7.58
$1.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
3.2K
1.1M
Earning Date
06-01-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.39
EPS
N/A
N/A
Revenue
$174,257,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.21
N/A
52 Week Low
$7.00
$1.36
52 Week High
$8.73
$5.50

Technical Indicators

Market Signals
Indicator
BRID
ANVS
Relative Strength Index (RSI) 46.14 37.87
Support Level $7.36 $1.57
Resistance Level $8.06 $2.99
Average True Range (ATR) 0.29 0.20
MACD -0.01 -0.03
Stochastic Oscillator 13.02 19.47

Price Performance

Historical Comparison
BRID
ANVS

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.

Share on Social Networks: